Bone loss after cardiac transplantation: Effects of calcium, calcidiol and monofluorophosphate

Meys, E.; Terreaux-Duvert, F.; Beaume-Six, T.; Dureau, G; Meunier, Pierre J.

doi:10.1007/bf01637318

Cited by 99 publications

(31 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…From mere "standard methods" (22), passing through "sera were measured using a specific F ion-sensitive electrode" (23) to "F concentration in serum were performed by laboratories located in four local universities laboratories using ion-specific potentiometry and were quality controlled" (24).…”

Section: Accuracy and Precision Of The Proposed Techniquementioning

confidence: 99%

Measurement of total and diffusible serum fluoride

Rigalli¹,

Alloatti²,

Puche³

1999

J. Clin. Lab. Anal.

View full text Add to dashboard Cite

This article describes a technique for the measurement of total and diffusible F content of serum, at clinical significant concentrations of F (1–10 μM). The proposed procedure avoids the interference of unknown serum components with the ion‐specific electrode. Sample F is concentrated fivefold through distillation of hydrofluoric acid (Taves' method). Ionic fluoride is presented to the electrode in a simple solution at concentrations within the linear response of the electrode. Average recoveries of F from serum or its ultrafiltrate were 96 ± 7% (21%) and 97 ± 12% (53%) (mean ± SEM [CV]), respectively. With four replicates of each sample, the technique produce within‐run standard deviations of 0.6 μM and 2.2 μM at 1 and 10 μM F, respectively. Total precision assessment gave standard deviations of 0.6 μM and 2.6 μM at 1 and 10 μM F, respectively. The fasting serum F levels of normal climacteric women, 45 to 65 years, showed an asymmetric distribution. The data obtained started at the detection limit of the technique (0.1 mM). The 75 percentile was 1.85 μM for total and 0.5 μM for diffusible F. In patients (n = 25) treated with NaF (30 mg F/day) the fasting levels of total serum F (4.5 ± 1.7 μM) did not differ from those of diffusible F (4.2 ± 1.5 μM). In patients (n = 50) treated with sodium monofluorophosphate (15 mg F/day) the fasting levels of total and diffusible serum F were 6.5 ± 1.7 μM and 0.5 ± 0.03 μM, respectively.In conclusion, this paper establishes the presence of two fractions of serum fluorine: diffusible and nondiffusible (or protein bound) and describes a technique for their clinical estimation. In untreated subjects and in patients receiving NaF, the former fraction contains ionic fluoride. In patients treated with MFP, diffusible serum fluorine is composed by ionic fluoride and low molecular weight, peptide‐bound, acid‐labile fluorine. J. Clin. Lab. Anal. 13:151–157, 1999. © 1999 Wiley‐Liss, Inc.

show abstract

Section: Accuracy and Precision Of The Proposed Techniquementioning

confidence: 99%

Measurement of total and diffusible serum fluoride

Rigalli¹,

Alloatti²,

Puche³

1999

J. Clin. Lab. Anal.

View full text Add to dashboard Cite

show abstract

“…Following liver and heart trans plantation, treatment with fluoride resulted in increased bone mass and reduced fracture rates in a small series [33,63]. In view o f the low turnover bone remodelling that is present in patients with liver disease, a beneficial effect of osteoblast stimulation by fluoride seems reasonable, but may not apply to renal graft recipients with hyperparathy roid bone disease.…”

Section: Hyperparathyroidismmentioning

confidence: 99%

Hyperparathyroidism and Bone Loss in Renal Graft Recipients

Ittel¹,

Schmitt²,

Sieberth³

1997

Kidney Blood Press Res

View full text Add to dashboard Cite

“…The use of corticosteroids is followed by spinal compression fracture in up to 35~ of patients [11. Moreover, some investigators have observed a 20% decrease in bone mineral density in patients with congestive heart failure awaiting transplantation [1,2~ but not others [3,41. In order to permit further understanding of the mechanism involved in such demineralisation, We studied bone mineral density and plasma calciotropic hormone levels in 30 male patients awaiting heart transplantation.…”

Section: Introductionmentioning

confidence: 99%

Mineralisation of precardiac transplantation patients: A key role for parathormone

et al. 1994

View full text Add to dashboard Cite

A bstract:Most studies find that precardiac transplantation patients are poorly mineralized; up to 35~ them suffer from vertebral crush fracture after transplantation. We studied 30 consecutives males cardiac transplant candidates. The mean age was 50.2-+1.5 years (mean-+SE). Creatinine clearance (82.3-+5.l ml/mn), 25 OH vitamin D (8.9--+0.7 ng/ml) and osteocalcin level (22.6+2.4 ng/ml) were in the normal ranges. Mean bone mineral density was low either at lumbar spine (0.905-+ 0.027 gr--+cm 2) or at femoral neck (0.829-+0.021 gr/cm 2) (Hologic QDR 1000). Mean Z scores were also low: -1.30-+0.24 at lumbar spine, -1.61-+0.19 at femoral neck. Parathormone (1-84) level was elevated (53.1-+6.8 ng/ml). Parathormone level was highly correlated with lumbar (r=0.512; p=0.004) or femoral @--0.579; p=0.001) bone mineral density as with lumbar @=0.524; p=0.003) or femoral @=0.606; p=0.0004) Z scores. Two parameters are highly correlated with parathormone level : _ daily posology of furosemide @=0.609 ; p=0.0005) _ atrial natriuretic factor level @=0.449 ; p=0.0128) Thus, most of the demineralisation of the cardiac transplant candidates is iatrogenic and result from furosemid therapy. Cardiac insufficiency could have a direct role, but the exact mechanism remain unclear.

show abstract

Bone loss after cardiac transplantation: Effects of calcium, calcidiol and monofluorophosphate

Cited by 99 publications

References 20 publications

Measurement of total and diffusible serum fluoride

Measurement of total and diffusible serum fluoride

Hyperparathyroidism and Bone Loss in Renal Graft Recipients

Mineralisation of precardiac transplantation patients: A key role for parathormone

Contact Info

Product

Resources

About